G. Abou-alfa, L. Schwartz, and S. Ricci, Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma, Journal of Clinical Oncology, vol.24, issue.26, pp.4293-300, 2006.
DOI : 10.1200/JCO.2005.01.3441

R. Abraham and J. Gibbons, The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy, Clinical Cancer Research, vol.13, issue.11, pp.3109-3123, 2007.
DOI : 10.1158/1078-0432.CCR-06-2798

A. Adjeij, Signal Transduction Pathway Targets for Anticancer Drug Discovery, Current Pharmaceutical Design, vol.6, issue.4, pp.361-378, 2000.
DOI : 10.2174/1381612003400821

J. Allen, A. Adlakha, and P. Bergethon, Reversible Posterior Leukoencephalopathy Syndrome After Bevacizumab/FOLFIRI Regimen for Metastatic Colon Cancer, Archives of Neurology, vol.63, issue.10, pp.1475-1483, 2006.
DOI : 10.1001/archneur.63.10.1475

A. Arsham, D. Plas, and C. Thompson, Phosphatidylinositol 3-Kinase/Akt Signaling Is Neither Required for Hypoxic Stabilization of HIF-1?? nor Sufficient for HIF-1-dependent Target Gene Transcription, Journal of Biological Chemistry, vol.60, issue.17, pp.15162-70, 2002.
DOI : 10.1074/jbc.M100677200

M. Backer, Inhibition of Vascular Endothelial Growth Factor Receptor Signaling in Angiogenic Tumor Vasculature, Adv Genet, vol.67, pp.1-27, 2009.
DOI : 10.1016/S0065-2660(09)67001-2

L. Benjamin, I. Hemo, and E. Keshet, A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed enfothelial network and is regulated by PDGF-b and VEGF, Development, vol.125, pp.1591-98, 1998.

G. Bergers, Angiogenesis: Tumorigenesis and the angiogenic switch, Nature Reviews Cancer, vol.3, issue.6, pp.401-411, 2002.
DOI : 10.1038/nrc1093

B. Blanchet, B. Billemont, S. Barete, H. Garrigue, L. Cabanes et al., Toxicity of sorafenib: clinical and molecular aspects, Expert Opinion on Drug Safety, vol.3, issue.2, pp.275-287, 2010.
DOI : 10.1158/1078-0432.CCR-06-0051

V. Boige, J. Barbare, and O. Rosmorduc, Utilisation du soraf??nib (Nexavar??) dans le traitement du carcinome h??patocellulaire??: recommandations Prodige Afef, Gastroent??rologie Clinique et Biologique, vol.32, issue.1, pp.3-7, 2008.
DOI : 10.1016/j.gcb.2007.11.001

A. Boulay, S. Zumstein-mecker, and C. Stephan, Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells, Cancer Research, vol.64, issue.1, pp.252-61, 2004.
DOI : 10.1158/0008-5472.CAN-3554-2

R. Bukowski, U. Yasothan, P. Kirkpatrick, and P. , Pazopanib, Nature Reviews Drug Discovery, vol.372, issue.1, pp.17-25, 2010.
DOI : 10.1038/nrd3073

P. Carmeliet, Blood vessels and nerves: common signals, pathways and diseases, Nature Reviews Genetics, vol.107, issue.9, pp.710-730, 2003.
DOI : 10.1046/j.1469-7580.2000.19740591.x

T. Chapman, C. Perry, and . Everolimus, Everolimus, Drugs, vol.349, issue.23, pp.861-72, 2004.
DOI : 10.2165/00003495-200464080-00005

R. Cohen, H. Bihan, B. Uzzan, G. Des-guetz, A. Krivitzky et al., Sunitinib et??hypothyro??die, Mise au point, pp.332-338, 2007.
DOI : 10.1016/j.ando.2007.06.027

R. Connolly, C. Doherty, P. Beddy, O. Byrne, and K. , Chemotherapy induced reversible posterior leukoencephalopathy syndrome, Lung Cancer, vol.56, issue.3, pp.459-63, 2007.
DOI : 10.1016/j.lungcan.2007.01.012

J. Desai, L. Yassa, and E. Marqusee, Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors, Annals of Internal Medicine, vol.145, issue.9, pp.660-664, 2006.
DOI : 10.7326/0003-4819-145-9-200611070-00008

C. Dreyer, S. Faivre, M. Serova, and R. E. , Métabolisme cellulaire : la signalisation de mTOR comme cible liée au métabolisme et à la synthèse des protéines in Le concept de cible en cancérologie, 2008.

C. Dunn and K. Croom, Everolimus, Drugs, vol.79, issue.2, pp.547-70, 2006.
DOI : 10.2165/00003495-200666040-00009

V. Eremina, M. Sood, and J. Haigh, Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases, Journal of Clinical Investigation, vol.111, issue.5, pp.707-723, 2003.
DOI : 10.1172/JCI17423

B. Escudier, Signaling Inhibitors in Metastatic Renal Cell Carcinoma, The Cancer Journal, vol.14, issue.5, pp.325-334, 2008.
DOI : 10.1097/PPO.0b013e3181867605

B. Escudier, T. Eisen, and W. Stadler, Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-159, 2007.
DOI : 10.1056/NEJMoa060655

S. Faivre, G. Kroemer, and R. E. , Current development of mTOR inhibitors as anticancer agents, Nature Reviews Drug Discovery, vol.10, issue.Abs. LBA 4, pp.671-88, 2006.
DOI : 10.1158/1078-0432.CCR-04-0035

J. Feige, Les facteurs de croissance de l'endothélium vasculaire et leurs récepteurs in L'angiogenèse, 2009.

N. Ferrara, H. Gerber, and J. Lecouter, The biology of VEGF and its receptors, Nature Medicine, vol.99, issue.21, pp.669-76, 2003.
DOI : 10.1073/pnas.152324099

K. Flaherty, Sorafenib: delivering a targeted drug to the right targets, Expert Review of Anticancer Therapy, vol.23, issue.5, pp.617-626, 2007.
DOI : 10.1200/jco.2005.23.16_suppl.3037

J. Forsythe, B. Jiang, and N. Iyer, Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1., Molecular and Cellular Biology, vol.16, issue.9, pp.4604-4617, 1996.
DOI : 10.1128/MCB.16.9.4604

J. Frampton and L. , Lapatinib, Drugs, vol.14, issue.1, pp.2125-2148, 2009.
DOI : 10.1016/S1359-6349(07)70874-1

P. Gaur, Targeting Tumor Angiogenesis, Seminars in Oncology, vol.36, pp.12-19, 2009.
DOI : 10.1053/j.seminoncol.2009.02.002

R. Govindarajan, J. Adusumilli, D. Baxter, A. El-khoueiry, and S. Harik, Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006, Journal of Clinical Oncology, vol.24, issue.28, p.48, 2006.
DOI : 10.1200/JCO.2006.08.4608

J. Grenier, C. Delbaldo, D. Pouessel, and S. Culine, Ciblage pharmacologique des récepteurs du facteur de croissance de l'endothélium vasculaire in L'angiogenèse, 2009.

J. Halimi, M. Azizi, and G. Bobrie, Effets vasculaires et r??naux des m??dicaments anti-angiog??niques??: recommandations fran??aises pour la pratique (SN, SFHTA, APNET, FFCD), N??phrologie & Th??rapeutique, vol.4, issue.7, pp.602-617, 2008.
DOI : 10.1016/j.nephro.2008.10.002

D. Hanahan and R. Weinberg, The Hallmarks of Cancer, Cell, vol.100, issue.1, pp.57-70, 2000.
DOI : 10.1016/S0092-8674(00)81683-9

C. Hartford and M. Ratain, Rapamycin: Something Old, Something New, Sometimes Borrowed and Now Renewed, Clinical Pharmacology & Therapeutics, vol.431, issue.4, pp.381-389, 2007.
DOI : 10.4049/jimmunol.177.2.944

A. Hertig, Angiogenesisin the early human chorion and in the primary placenta of the macaque monkey, Contrib Embryol Caregie Inst Washington, vol.25, pp.37-38, 1935.

D. Hicklin, Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis, Journal of Clinical Oncology, vol.23, issue.5, pp.1011-1038, 2005.
DOI : 10.1200/JCO.2005.06.081

T. Holbro, The ErbB receptors and their role in cancer progression, Experimental Cell Research, vol.284, issue.1, pp.99-110, 2033.
DOI : 10.1016/S0014-4827(02)00099-X

T. Holbro and N. Hynes, : Directing Key Signaling Networks Throughout Life, Annual Review of Pharmacology and Toxicology, vol.44, issue.1, pp.195-217, 2004.
DOI : 10.1146/annurev.pharmtox.44.101802.121440

P. Hubert, Growth factors of the EGF family and their receptors, Bull Cancer, vol.hors série, pp.17-24, 2006.

R. Humar, F. Kiefer, and H. Berns, Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) -dependent signaling, The FASEB Journal, vol.16, issue.8, pp.771-80, 2002.
DOI : 10.1126/science.2343305

Y. Izumiya, . Shiojima, K. Sato, W. Colucci, and K. Walsh, Vascular Endothelial Growth Factor Blockade Promotes the Transition From Compensatory Cardiac Hypertrophy to Failure in Response to Pressure Overload, Hypertension, vol.47, issue.5, pp.887-93, 2006.
DOI : 10.1161/01.HYP.0000215207.54689.31

B. Kahan, Optimization of cyclosporine therapy, Transplant Proc, vol.25, pp.5-9, 2003.

T. Kamba and D. Mcdonald, Mechanisms of adverse effects of anti-VEGF therapy for cancer, British Journal of Cancer, vol.280, issue.12
DOI : 10.1038/nm1428

T. Kamba, B. Tam, and . Hashizume, VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature, American Journal of Physiology-Heart and Circulatory Physiology, vol.290, issue.2, pp.560-76, 2006.
DOI : 10.1016/S0002-9440(10)62567-9

P. Karly, G. M. Garnock-jones, and . Keating, Everolimus, in advanced renal cell carcinoma, Drugs, vol.69, issue.15, pp.2115-2124, 2009.

H. Kelly, D. Ferry, L. Hammond, M. Kris, E. Rovinsky et al., Iressa ® " ), an oral EGFR-TKI (epidermal growth factor tyrosine kinase inhibitor) : pharmacokinetic results of a phase I study in patients with advanced cancer, Proc Am Ass Cancer Res, vol.41, p.612, 2000.

M. Kris, M. Ranson, D. Ferry, L. Hammond, S. Averbuch et al., Phase I study of oral ZD 1839 Iressa ® " ), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFr- TKI) : evidence of good tolerability and activity, Poster, vol.99, 1999.

G. Kroog and R. Motzer, Systemic Therapy for Metastatic Renal Cell Carcinoma, Urologic Clinics of North America, vol.35, issue.4, pp.687-701, 2008.
DOI : 10.1016/j.ucl.2008.07.007

H. Lane, J. Wood, and P. Mcsheehy, mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor, Clinical Cancer Research, vol.15, issue.5, pp.1612-1634, 2009.
DOI : 10.1158/1078-0432.CCR-08-2057

C. Lathia, J. Lettieri, and F. Cihon, Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics, Cancer Chemotherapy and Pharmacology, vol.30, issue.5, pp.685-92, 2006.
DOI : 10.5414/CPP40580

B. Lévy, Microvascular Plasticity and Experimental Heart Failure, Hypertension, vol.47, issue.5, pp.827-836, 2006.
DOI : 10.1161/01.HYP.0000215283.53943.39

N. Lin and E. Winer, New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors, Breast Cancer Research, vol.82, issue.Suppl 1, pp.204-214, 2004.
DOI : 10.1093/jnci/djg117

J. Llovet, S. Ricci, and V. Mazzaferro, Sorafenib in Advanced Hepatocellular Carcinoma, New England Journal of Medicine, vol.359, issue.4, pp.378-90, 2008.
DOI : 10.1056/NEJMoa0708857

S. Loges, Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited, Cancer Cell, vol.15, issue.3
DOI : 10.1016/j.ccr.2009.02.007

URL : https://doi.org/10.1016/j.ccr.2009.02.007

S. Ménard, Overexpression and Other Tumor Biologic Variables, Journal of Clinical Oncology, vol.19, issue.2, pp.329-364, 2001.
DOI : 10.1200/JCO.2001.19.2.329

G. Milano, Les molécules spécifiques des cibles membranaires in Le concept de cible en cancérologie, 2008.

N. Moghal and P. Sternberg, Multiple positive and negative regulators of signaling by the EGF-receptor, Current Opinion in Cell Biology, vol.11, issue.2, pp.190-196, 1999.
DOI : 10.1016/S0955-0674(99)80025-8

L. Monnier, Targeting of membrane receptor tyrosine kinases : is there resistance in the HER?, Bull Cancer, vol.91, issue.9, pp.685-94, 2004.

A. Morabito, D. Maio, E. , D. Maio, and M. , Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions, The Oncologist, vol.11, issue.7, pp.753-64, 2006.
DOI : 10.1634/theoncologist.11-7-753

J. Mourad and B. Lévy, Toxicité cardio-vasculaire des thérapeutiques anti-angiogènes in L'angiogenèse, p.134, 2009.

D. Niculescu-duvaz, S. Whittaker, and C. Springer, The EGF Receptor Hokey-Cokey, Cancer Cell, vol.11, issue.3, pp.209-220, 2007.
DOI : 10.1016/j.ccr.2007.02.021

S. Noonberg and C. Benz, Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor Subfamily, Drugs, vol.11, issue.4, pp.753-767, 2000.
DOI : 10.3109/10428199809057550

N. Normanno, Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment, Endocrine Related Cancer, vol.10, issue.1, pp.1-21, 2003.
DOI : 10.1677/erc.0.0100001

J. Osbourn, L. Jermutus, and A. Duncan, Current methods for the generation of human antibodies for the treatment of autoimmune diseases, Drug Discovery Today, vol.8, issue.18, pp.845-851, 2003.
DOI : 10.1016/S1359-6446(03)02803-4

D. Pouessel and S. Culine, High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor, European Urology, vol.53, issue.2, pp.376-81, 2008.
DOI : 10.1016/j.eururo.2007.08.053

K. Pritchard, and Responsiveness of Breast Cancer to Adjuvant Chemotherapy, New England Journal of Medicine, vol.354, issue.20, pp.2103-2114, 2006.
DOI : 10.1056/NEJMoa054504

Z. Qu, G. Griffiths, and W. Wegener, Development of humanized antibodies as cancer therapeutics, Methods, vol.36, issue.1, pp.84-95, 2005.
DOI : 10.1016/j.ymeth.2005.01.008

M. Ratain, T. Eisen, and W. Stadler, Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.24, issue.16, pp.2505-2517, 2006.
DOI : 10.1200/JCO.2005.03.6723

E. Raymond, Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy, Drugs, vol.3, issue.2-3, pp.15-23, 2000.
DOI : 10.2165/00003495-200060001-00002

P. Rodriguez-viciana, Phosphatidylinositol-3-OH kinase direct target of Ras, Nature, vol.370, issue.6490, pp.527-559, 1994.
DOI : 10.1038/370527a0

E. Rowinsky and S. Events, Signal Events: Cell Signal Transduction and Its Inhibition in Cancer, The Oncologist, vol.8, issue.90003, pp.5-17, 2003.
DOI : 10.1634/theoncologist.8-suppl_3-5

E. Rowinsky, Targeting signal transduction, the erbB receptor family as a target for therapeutic development. Horizons in Cancer Therapeutics : From Bench to, Bedside, vol.2, issue.2, pp.3-35, 2001.

H. Rugo, R. Herbst, and G. Liu, Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results, Journal of Clinical Oncology, vol.23, issue.24, pp.5474-83, 2005.
DOI : 10.1200/JCO.2005.04.192

D. Rusnak, K. Lackey, and K. Affleck, The effects of the novel, reversible epidermal growth factor receptor / ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro andin vivo, Mol Cancer Ther, vol.1, pp.85-94, 2001.

E. Shinohara, C. Cao, and K. Niermann, Enhanced radiation damage of tumor vasculature by mTOR inhibitors, Oncogene, vol.24, issue.35, pp.5414-5436, 2005.
DOI : 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.0.CO;2-S

I. Shiojima, K. Sato, and Y. Izumiya, Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure, Journal of Clinical Investigation, vol.115, issue.8, pp.2108-2126, 2005.
DOI : 10.1172/JCI24682

C. Sternberg, I. Davis, and J. Mardiak, Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.28, issue.6, pp.1061-1069, 2010.
DOI : 10.1200/JCO.2009.23.9764

I. Tamaskar, R. Bukowski, and P. Elson, Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib, Annals of Oncology, vol.19, issue.2, pp.265-273, 2008.
DOI : 10.1093/annonc/mdm483

F. Torino, S. Corsello, and R. Longo, Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy, Nature Reviews Clinical Oncology, vol.18, issue.4, pp.219-247, 2009.
DOI : 10.7326/0003-4819-145-9-200611070-00015

T. Velu and . Structure, Structure, function and transforming potential of the epidermal growth factor receptor, Molecular and Cellular Endocrinology, vol.70, issue.3, pp.205-216, 1990.
DOI : 10.1016/0303-7207(90)90211-P

C. Vezina, A. Kudelski, and S. Sehgal, Rapamucin (AY-22, 989), a new antifungal antibiotic. I

P. Wan, M. Garnett, and S. Roe, Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF, Cell, vol.116, issue.6, pp.855-67, 2004.
DOI : 10.1016/S0092-8674(04)00215-6

S. Wilhelm, C. Carter, and L. Tang, BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis, Cancer Research, vol.64, issue.19, pp.7099-109, 2004.
DOI : 10.1158/0008-5472.CAN-04-1443

C. Willet, Y. Boucher, D. Tomaso, and E. , Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer, Nature Medicine, vol.15, issue.2, pp.145-192, 2004.
DOI : 10.1007/BF00437479

W. Xia, R. Mullin, and B. Keith, Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways, Oncogene, vol.21, issue.41, pp.6255-6263, 2002.
DOI : 10.1038/sj.onc.1202319

C. Yang, W. Lin, and C. Chuang, Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy, British Journal of Dermatology, vol.24, issue.3, pp.592-598, 2008.
DOI : 10.1111/j.1365-2133.2007.08357.x

. Sujet, Inhibiteurs de tyrosine kinase utilisés dans les tumeurs solides: proposition de fiches d'utilisation pratique destin ées à l'équipe officinale Jury: Président : Monsieur le Professeur MERLIN Directeur: Madame Béatrice DEMORE Juges

. Vu and . Nancy, ('l\(~ 2.P \ Doyen de la Faculté de Pharmacie de l